TTP Plc And Innova Biosciences Extend Partnership To Develop Rapid Point-Of-Care Diagnostics

Cambridge, UK, 13 June 2017: TTP plc, Europe's leading technology and product development company, today announces its ongoing partnership with Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, to enable its rapid point-of-care diagnostics development program.

TTP’s Desktop Biology provides fast track development and rapid route to market for companies looking to commercialise their assays. Innova is providing custom magnetic beads and alkaline phosphatase conjugation services, to support the conjugate screening phases of TTP’s assay development. 

The original custom project, under which Innova developed magnetic bead conjugation previously not offered either off-the-shelf or as a custom service, involved developing a range of magnetic beads of different diameters conjugated to capture antibodies. Innova produced all conjugates within 1 week of receiving antibody material. Following the success of this initial project the companies are planning to continue to collaborate, to offer a seamless approach for companies looking to accelerate the development of their diagnostic or research assays.

The relationship with Innova Biosciences will further strengthen the services TTP provides to its customers by innovating and expanding its offering of new diagnostic systems to the market.

Nick Gee, CEO and CSO at Innova Biosciences, commented: “We are pleased to be supporting TTP in the development of point-of-care diagnostics. The immunodiagnostics market continues to expand worldwide, and this therefore presents an exciting opportunity for both Innova and TTP.”

Edwin Stone, at TTP plc, said: “By offering a full-service assay and hardware development solution, TTP is able to provide its clients with greatly reduced time to market. Our relationship with Innova expands and reinforces our Desktop Biology service, enabling our clients to achieve a competitive advantage.”